It has been suggested that if Sanofi, a French pharmaceutical company, succeeds in developing a vaccine for coronavirus infection-19 (Corona 19), it will set a price of less than 10 euros (about 14,000 won).

According to the Reuters news agency on the 6th (local time), France's CEO Olivier Bogilo Sanofi (CEO) delivered the current status of the Corona 19 vaccine development through an interview with French Interradio.

"The price has not yet been fully set, and we will evaluate the cost of production over the next few months," he said. "It will be under 10 euros."

Regarding the prospect that AstraZeneca, a multinational pharmaceutical company, is working with Oxford University to set the cost of the Corona 19 vaccine being developed in Europe at 2.5 euros (about 3,500 won), he said, "We are using internal resources, research, and researchers. "There may be a price difference in outsourcing part of the production for AstraZeneca."

In an email statement, a spokesman for Sanofi said the price of the COVID-19 vaccine will only be determined after the last successful clinical trial.

"We expect to be able to determine the final price only after phase 3 clinical trials, when we learn more about the vaccine," said a spokesman. "Neither number is inaccurate at this stage. Below 10 euros is one of many assumptions we are working on." Said.

Sanofi, which is developing a vaccine in partnership with GlaxoSmithKline (GSK) in the UK, announced that it began clinical trials of a protein-assisted COVID-19 vaccine earlier this month, and expects to reach the final phase of clinical trials by December.

If the results are positive, Sanofi and GSK expect to receive vaccine approval in the first half of next year.

Separately, Sanofi is developing a COVID-19 vaccine using US transrate bio and messenger ribonucleic acid (mRNA, messenger RNA).

(yunhap news)